Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2016

Open Access 01-08-2016 | Preclinical study

Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families

Authors: Taru A. Muranen, Nasim Mavaddat, Sofia Khan, Rainer Fagerholm, Liisa Pelttari, Andrew Lee, Kristiina Aittomäki, Carl Blomqvist, Douglas F. Easton, Heli Nevanlinna

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Login to get access

Abstract

The risk of developing breast cancer is increased in women with family history of breast cancer and particularly in families with multiple cases of breast or ovarian cancer. Nevertheless, many women with a positive family history never develop the disease. Polygenic risk scores (PRSs) based on the risk effects of multiple common genetic variants have been proposed for individual risk assessment on a population level. We investigate the applicability of the PRS for risk prediction within breast cancer families. We studied the association between breast cancer risk and a PRS based on 75 common genetic variants in 52 Finnish breast cancer families including 427 genotyped women and pedigree information on ~4000 additional individuals by comparing the affected to healthy family members, as well as in a case–control dataset comprising 1272 healthy population controls and 1681 breast cancer cases with information on family history. Family structure was summarized using the BOADICEA risk prediction model. The PRS was associated with increased disease risk in women with family history of breast cancer as well as in women within the breast cancer families. The odds ratio (OR) for breast cancer within the family dataset was 1.55 [95 % CI 1.26–1.91] per unit increase in the PRS, similar to OR in unselected breast cancer cases of the case–control dataset (1.49 [1.38–1.62]). High PRS-values were informative for risk prediction in breast cancer families, whereas for the low PRS-categories the results were inconclusive. The PRS is informative in women with family history of breast cancer and should be incorporated within pedigree-based clinical risk assessment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399CrossRef
2.
go back to reference Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA (2009) Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 100:421–425. doi:10.1038/sj.bjc.6604830 CrossRefPubMed Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA (2009) Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 100:421–425. doi:10.​1038/​sj.​bjc.​6604830 CrossRefPubMed
3.
go back to reference Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25:5898–5905CrossRefPubMed Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25:5898–5905CrossRefPubMed
8.
go back to reference French JD, Ghoussaini M, Edwards SL et al (2013) Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet. doi:10.1016/j.ajhg.2013.01.002 French JD, Ghoussaini M, Edwards SL et al (2013) Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet. doi:10.​1016/​j.​ajhg.​2013.​01.​002
9.
go back to reference National Collaborating Centre for Cancer (UK) (2013). DOI:NBK247567 [bookaccession] National Collaborating Centre for Cancer (UK) (2013). DOI:NBK247567 [bookaccession]
10.
go back to reference Dite GS, MacInnis RJ, Bickerstaffe A et al (2015) Breast cancer risk prediction using clinical models and 77 independent risk-associated snps for women aged under 50 years: Australian Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 25:359–365CrossRefPubMed Dite GS, MacInnis RJ, Bickerstaffe A et al (2015) Breast cancer risk prediction using clinical models and 77 independent risk-associated snps for women aged under 50 years: Australian Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 25:359–365CrossRefPubMed
11.
go back to reference Vachon CM, Pankratz VS, Scott CG et al (2015) The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst. doi:10.1093/jnci/dju397 Vachon CM, Pankratz VS, Scott CG et al (2015) The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst. doi:10.​1093/​jnci/​dju397
12.
go back to reference Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529–1531CrossRefPubMed Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529–1531CrossRefPubMed
13.
go back to reference Kilpivaara O, Bartkova J, Eerola H et al (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575–580. doi:10.1002/ijc.20638 CrossRefPubMed Kilpivaara O, Bartkova J, Eerola H et al (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575–580. doi:10.​1002/​ijc.​20638 CrossRefPubMed
14.
go back to reference Fagerholm R, Hofstetter B, Tommiska J et al (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844–853. doi:10.1038/ng.155 CrossRefPubMed Fagerholm R, Hofstetter B, Tommiska J et al (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844–853. doi:10.​1038/​ng.​155 CrossRefPubMed
15.
go back to reference Vahteristo P, Bartkova J, Eerola H et al (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432–438CrossRefPubMedPubMedCentral Vahteristo P, Bartkova J, Eerola H et al (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432–438CrossRefPubMedPubMedCentral
16.
go back to reference Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H (2000) Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36:1143–1148CrossRefPubMed Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H (2000) Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36:1143–1148CrossRefPubMed
20.
go back to reference Heikkinen T, Karkkainen H, Aaltonen K, Milne RL, Heikkila P, Aittomaki K, Blomqvist C, Nevanlinna H (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 15:3214–3222. doi:10.1158/1078-0432.CCR-08-3128 CrossRefPubMed Heikkinen T, Karkkainen H, Aaltonen K, Milne RL, Heikkila P, Aittomaki K, Blomqvist C, Nevanlinna H (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 15:3214–3222. doi:10.​1158/​1078-0432.​CCR-08-3128 CrossRefPubMed
21.
go back to reference R Development Core Team (2012) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna R Development Core Team (2012) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
22.
go back to reference Graham N, Mahmood A, Hagströmer B (2015) multiwayvcov: Multi-way Standard Error Clustering, R package version 1.2.2 Graham N, Mahmood A, Hagströmer B (2015) multiwayvcov: Multi-way Standard Error Clustering, R package version 1.2.2
23.
go back to reference Zeileis A, Hothorn T (2002) Diagnostic checking in regression relationships. R News 2:7–10 Zeileis A, Hothorn T (2002) Diagnostic checking in regression relationships. R News 2:7–10
24.
go back to reference Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110:535–545. doi:10.1038/bjc.2013.730 CrossRefPubMed Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110:535–545. doi:10.​1038/​bjc.​2013.​730 CrossRefPubMed
27.
go back to reference Li H, Feng B, Miron A et al (2016) Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genet Med. doi:10.1038/gim.2016.43 Li H, Feng B, Miron A et al (2016) Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genet Med. doi:10.​1038/​gim.​2016.​43
Metadata
Title
Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families
Authors
Taru A. Muranen
Nasim Mavaddat
Sofia Khan
Rainer Fagerholm
Liisa Pelttari
Andrew Lee
Kristiina Aittomäki
Carl Blomqvist
Douglas F. Easton
Heli Nevanlinna
Publication date
01-08-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3897-6

Other articles of this Issue 3/2016

Breast Cancer Research and Treatment 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine